UroGen Pharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a URGN research report →
About the company
UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
- CEO
- Elizabeth Barrett
- IPO
- 2017
- Employees
- 291
- HQ
- Princeton, NJ, US
Price Chart
- Market Cap
- $1.85B
- P/E
- -13.83
- P/S
- 13.18
- P/B
- -15.36
- EV/EBITDA
- -16.74
- Div Yield
- 0.00%
- Gross Margin
- 89.85%
- Op Margin
- -77.02%
- Net Margin
- -94.83%
- ROE
- 121.52%
- ROIC
- -50.85%
- Revenue
- $109.79M · 21.45%
- Net Income
- $-153,494,000 · -20.98%
- EPS
- $-3.19 · -7.77%
- Op Income
- $-124,863,000
- FCF YoY
- -67.66%
- 52W High
- $39.59
- 52W Low
- $13.26
- 50D MA
- $29.27
- 200D MA
- $22.84
- Beta
- 1.62
- Avg Volume
- 806.16K
Get TickerSpark's AI analysis on URGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 26 | Schoenberg Mark | sell | 10,000 |
| Jun 22, 26 | Wildman Daniel George | other | 10,000 |
| Jun 22, 26 | Wildman Daniel George | other | 8,000 |
| Jun 22, 26 | Robinson James A. Jr. | other | 10,000 |
| Jun 22, 26 | Robinson James A. Jr. | other | 8,000 |
| Jun 22, 26 | Holden Stuart | other | 20,000 |
| Jun 22, 26 | BUTITTA CYNTHIA M | other | 10,000 |
| Jun 22, 26 | BUTITTA CYNTHIA M | other | 8,000 |
| Jun 22, 26 | WEN LEANA | other | 10,000 |
| Jun 22, 26 | WEN LEANA | other | 8,000 |
Our URGN coverage
Recent articles, reports, and earnings notes.
No research on URGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate URGN report →Similar companies
Peers in the same neighborhood.